The end is nigh for GSK's darapladib
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline's investigational Lp-PLA 2 inhibitor darapladib has failed in a second Phase III study, SOLID-TIMI 52, all but extinguishing any hopes for the product.